Curaleaf Asks Alberta Regulator to Halt Aurora Share Sales During Takeover Bid

By Nicolás Rodríguez, Managing Editor

Curaleaf Holdings has asked the Alberta Securities Commission to halt Aurora Cannabis’ at-the-market share issuance program. At the same time, its takeover offer remains outstanding, escalating the companies’ increasingly contentious acquisition battle.

In its application, Curaleaf characterized Aurora’s continued share issuances as an “improper and abusive defensive tactic” and requested an expedited hearing.

Curaleaf said Aurora issued approximately 2.81 million shares at an average price of US$3.04 after the companies began discussing a potential transaction in June. According to the filing, those issuances diluted existing shareholders by approximately 4.9% and increased the cost of Curaleaf’s offer by more than US$11 million. Since Aurora established the ATM program in February, cumulative dilution has reached approximately 10.8%.

“Every Share Aurora sells below the Offer price raises the same question: if management believes US$4.00 undervalues the company and the company has ample cash, why continue diluting its shareholders?” Curaleaf Executive Chairman and CEO Boris Jordan said.

Key Points

• Curaleaf wants the Alberta Securities Commission to halt Aurora’s ATM issuances for the duration of its offer.
• The company argues that additional shares raise the acceptance threshold and could interfere with shareholders’ consideration of the proposal.
• The application questions Aurora’s need to raise capital because the company describes itself as debt-free, reports approximately C$149 million in cash and previously said ATM proceeds would fund strategic and accretive purposes.
• The filing does not establish that Aurora violated securities law. The commission must determine whether the ATM program warrants intervention.
• Curaleaf’s pending US$4-per-share offer would combine two major international cannabis platforms.
• Aurora maintains that the proposal undervalues the company and has advised shareholders not to tender.

What the Curaleaf–Aurora Deal Mechanics Reveal

The issues raised in Curaleaf’s application—dilution and the US$4-per-share valuation—are central to the offer’s cost and whether shareholders have an incentive to tender. Every new share affects the deal mechanics while the market price reflects investors’ assessment of the offer’s value and likelihood of completion.

In his latest analysis for Ignite It, Chief Economic Columnist Rolando García examines those mechanics and the competing interpretations. Does Aurora’s share price indicate that investors expect a higher bid, or does it reflect uncertainty that the existing offer will close? Read García’s full breakdown of the Curaleaf–Aurora deal mechanics to understand how dilution and market pricing are shaping the takeover battle.